News 

November 28, 2022

Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference
Read more »

October 17, 2022

Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer
Read more »

October 27, 2021

Marc Schneebaum Joins Avalyn Pharma as Chief Financial Officer
Read more »

May 24, 2021

Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial
Read more »

October 16, 2020

Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
Read more »

April 27, 2020

Avalyn Pharma Secures $35.5 Million Series B Financing, Broadens Development Portfolio
Read more »

May 15, 2017

Genoa Pharmaceuticals Secures $62 Million Series A Financing, Adds to Leadership Team
Read more »

October 31, 2016

IPF Up and Comers Look to Add On Rather Than Compete
Read more »

September 3, 2014

Will Little-Known Company’s Inhaled Candidate Take Down InterMune-Roche’s Pirfenidone?
Read more »

August 5, 2014

Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Read more »

May 13, 2014

Genoa Pharmaceuticals to Present at the Annual American Thoracic Society International Conference
Read more »

April 21, 2014

Genoa Pharmaceuticals and McMaster University Demonstrate Inhaled Pharmacokinetics Enables Improved Pirfenidone Activity With Significant Promise to Enhance IPF Treatment Safety and Tolerability
Read more »

June 5, 2013

Genoa Pharmaceuticals and McMaster University Demonstrate in Vivo Benefit of Inhaled Pirfenidone Offering Greater Pulmonary Fibrosis Efficacy Than Oral Therapy
Read more »

January 16, 2013

Genoa Pharmaceuticals and McMaster University to Collaborate on Idiopathic Pulmonary Fibrosis Research
Read more »